Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment
Status:
Completed
Trial end date:
2019-08-19
Target enrollment:
Participant gender:
Summary
To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab
ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or
renal impairment